Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Símbolo de cotizaciónACON
Nombre de la empresaAclarion Inc
Fecha de salida a bolsaApr 22, 2022
Director ejecutivoNess (Brent)
Número de empleados6
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 22
Dirección8181 Arista Place
CiudadBROOMFIELD
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal80021
Teléfono18332752266
Sitio Webhttps://aclarion.com/
Símbolo de cotizaciónACON
Fecha de salida a bolsaApr 22, 2022
Director ejecutivoNess (Brent)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos